Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Cabaletta Bio, Inc.

Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform encompasses two strategies: the CARTA (chimeric antigen receptor T cells for autoimmunity) strategy, with CABA-201, a 4-1BB-containing fully human CD19-CAR T, as the lead product candidate being evaluated in systemic lupus erythematosus and myositis, and the CAART (chimeric autoantibody receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK myasthenia gravis. The expanding CABA™ platform is designed to develop potentially curative therapies that offer deep and durable responses for patients with a broad range of autoimmune diseases. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA.

5AM Ventures

Baker Brothers Advisors LLC

Boxer Capital

Cormorant Capital

Deerfield Capital Management

Penn Medicine Co-Investment Program

Redmile Group

Adage Capital Management

Cabaletta Bio

Cabaletta Bio recognizes and congratulates Georg Schett, innovator and global leader in the use of CD19-targeting cell therapies for patients with autoimmune diseases, along with his team on their landmark publication in the New England Journal of Medicine. Their academic case series study demonstrated durable clinical responses across 15 patients (8 with lupus, 3 with myositis and 4 with systemic sclerosis) treated with a 4-1BB co-stimulatory domain containing autologous CD19-CAR T construct. We believe these published data represent a pivotal moment in the effort to bring potentially transformative treatment to patients with a broad range of autoimmune diseases. #CART #autoimmunity #lupus #myositis #scleroderma https://lnkd.in/eU_KVCwH

Cabaletta Bio is excited to announce that the FDA has granted orphan drug designation to CABA-201 for the treatment of myositis. This designation is an important recognition for investigational therapies in rare diseases as we seek to deliver the first targeted, potentially curative, cell therapy for patients with autoimmune disease. Cabaletta's RESET-Myositis and RESET-SLE trials are currently enrolling patients [https://lnkd.in/eXEnYuh2, https://lnkd.in/eXHmWhbG] #CART #autoimmune #myositis. https://lnkd.in/exzwpp_n


Dr. Gwendolyn Binder PhD, President of Science and Technology at Cabaletta Bio, will be delivering the opening keynote presentation at the 7th annual Cell & Gene Therapy Innovation Summit where she will review the history and current state of art for engineered T cell therapy for patients with autoimmune diseases. Join us in Barcelona on Wednesday, February 7, 2024 in Barcelona for the presentation!

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-12.20M -	-16.94M 38.85%	-33.34M 96.77%	-46.29M 38.84%	-52.98M 14.44%	-67.67M 27.75%
depreciation and amortization		104K -	354K 240.38%	733K 107.06%	1.18M 60.71%	1.43M 21.05%
deferred income tax		-2.26M -
stock based compensation	606K -	2.30M 279.54%	4.39M 90.78%	5.80M 32.27%	6.90M 18.83%	11.34M 64.46%
change in working capital	-464K -	-1.51M 224.57%	1.71M 213.41%	5.58M 226.76%	-4.30M 177.03%	1.68M 138.96%
accounts receivables
inventory
accounts payables	234K -	246K 5.13%	555K 125.61%	975K 75.68%	-28K 102.87%	1.68M 6,082.14%
other working capital	-698K -	-1.75M 151.00%	1.15M 165.81%	4.61M 299.48%	-4.27M 192.73%	-1.68M 60.78%
other non cash items	7.40M -	2.26M 69.43%	119K 94.74%	62K 47.90%	2.82M 4,446.77%	1.36M 51.86%
net cash provided by operating activities	-4.66M -	-16.05M 244.24%	-26.77M 66.84%	-34.11M 27.42%	-46.38M 35.98%	-53.55M 15.46%
investments in property plant and equipment		-693K -	-635K 8.37%	-1.17M 83.62%	-2.45M 110.38%	-687K 71.99%
acquisitions net			7.35K -		24.76K -
purchases of investments			-11.10M -		-49.76M -	-84.26M 69.33%
sales maturities of investments			3.75M -	7.17M 91.02%	25M 248.92%	62.50M 150%
other investing activites			-7.35K -		-24.76K -
net cash used for investing activites		-693K -	-7.98M 1,051.66%	6.00M 175.17%	-27.22M 553.69%	-22.45M 17.51%
debt repayment		-10.09M -
common stock issued		71.21M -	29K 99.96%	48.25M 166,289.66%	32.85M 31.91%	185.20M 463.70%
common stock repurchased	-169K -	-1.29M 665.09%	-192K 85.15%	71K 136.98%	76K 7.04%	108K 42.11%
dividends paid		-10.09M -
other financing activites	37.85M -	70.19M 85.45%	139K 99.80%	579K 316.55%	51K 91.19%	2.32M 4,450.98%
net cash used provided by financing activities	37.68M -	119.92M 218.30%	-24K 100.02%	48.90M 203,862.50%	32.98M 32.56%	187.63M 468.89%
effect of forex changes on cash
net change in cash	33.02M -	103.19M 212.54%	-34.77M 133.70%	20.79M 159.79%	-40.62M 295.33%	111.63M 374.85%
cash at beginning of period	1K -	33.02M 3,301,600%	136.20M 312.53%	101.43M 25.53%	122.22M 20.50%	81.61M 33.23%
cash at end of period	33.02M -	136.20M 312.53%	101.43M 25.53%	122.22M 20.50%	81.61M 33.23%	193.24M 136.79%
operating cash flow	-4.66M -	-16.05M 244.24%	-26.77M 66.84%	-34.11M 27.42%	-46.38M 35.98%	-53.55M 15.46%
capital expenditure		-693K -	-635K 8.37%	-1.17M 83.62%	-2.45M 110.38%	-687K 71.99%
free cash flow	-4.66M -	-16.74M 259.11%	-27.41M 63.73%	-35.27M 28.72%	-48.83M 38.44%	-54.24M 11.06%

NASDAQ:CABA

Cabaletta Bio, Inc.

Last Close

12.69

16/05 14:08

Market Cap

954.68M

Beta: 2.53

Volume Today

77.83K

Avg: 390.10K

PE Ratio

−15.75

PFCF: −19.39